CR UK trials early-stage Lilly drug
Cancer Research UK has launched a new multi-site trial of an early-stage experimental therapy owned by Eli Lilly assessing its potential in a range of advanced cancers.
Read More
Tag: LY3143921 hydrate
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
